HSIC logo

HENRY SCHEIN INC

HSICNASDAQ
πŸ† #784 by market capEarnings Nov 2 Β· PreUS Equity
$89.18β–² $1.11 (+1.25%)
πŸŒ… Pre-market$89.01β–Ό 0.19%Regular close Β· extended-hours price shown
1hβ€”
24hβ–² 1.3%
7dβ–Ό 0.5%
14dβ–² 3.9%
30dβ–² 3.9%
1yβ–² 32.1%
🏦Market Cap
$10.16B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+6.5%
Slowing
πŸ“ŠGross Margin
31.3%
Moderate
πŸ’΅FCF Margin
4.8%
Moderate
βš–οΈP/S Ratio
0.7x
Cheap
Otter Score
49
Weak

Trading Snapshot

Day Range
$88.07 – $90.13
52-Week Range
$61.95 – $92.18
Volume
$2.58B
Avg Volume
$2.26B
Shares Outstanding
113.9M
Next Earnings
Sep 1, 2026

Fundamentals Snapshot

Annual Revenue
$13.18B
Last Q Revenue
$3.46B
P/E Ratio
24.3
P/S Ratio
0.7x
EPS (TTM)
$3.43
Dividend Yield
β€”

Why Investors Own HSIC

  • βœ“High-growth profile β€” revenue up +15.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 62% gross margin and 23% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$13.18Bβ–² +14.9% YoY
Gross Margin (TTM)
61.6%β–² +4.5% YoY
Operating Income (TTM)
$2.54Bβ–² +14.9% YoY
Free Cash Flow (TTM)
$3.06Bβ–² +14.9% YoY

About HENRY SCHEIN INC

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
49/100

Analyst Ratings

β“˜
Consensus
Buy
25 analysts
Strong Buy7
Buy7
Hold10
Sell1
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

YahooΒ·1d ago

Should Value Investors Buy Henry Schein (HSIC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

YahooΒ·5d ago

HSIC or SAUHY: Which Is the Better Value Stock Right Now?

HSIC vs. SAUHY: Which Stock Is the Better Value Option?

🌌
BenzingaΒ·6d ago

Barclays Maintains Overweight on Henry Schein, Raises Price Target to $100

Barclays analyst Glen Santangelo maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $86 to $100.

YahooΒ·6d ago

Should Henry Schein’s Raised 2026 Sales Growth Guidance Require Action From Henry Schein (HSIC) Investors?

Henry Schein, Inc. reported past Q2 2026 results with sales rising to US$3,458 million and net income to US$94 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. Importantly for long-term watchers, management also raised its 2026 total sales growth guidance, signaling greater confidence in the company’s operating initiatives and demand trends. Now we’ll examine how Henry Schein’s raised 2026 sales outlook reshapes its existing...

πŸ›°οΈ
BenzingaΒ·6d ago

UBS Maintains Neutral on Henry Schein, Raises Price Target to $94

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $89 to $94.

🌌
BenzingaΒ·6d ago

Citigroup Maintains Buy on Henry Schein, Raises Price Target to $112

Citigroup analyst Daniel Grosslight maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $112.